Encouraging Data On Amgen Candidate
Amgen (NASDAQ:AMGN) recently presented positive data on its hypercholesterolemia candidate, AMG145. Results were presented at the American College of Cardiology Scientific Session from a phase Ib study that was conducted in high cholesterol patients taking statins. Results in Detail AMG 145, a fully human monoclonal antibody, is a PCSK9 inhibitor. The phase Ib study (n=51) [...]
Amgen (AMGN) recently presented positive data on its hypercholesterolemia candidate, AMG145. Results were presented at the American College of Cardiology Scientific Session from a phase Ib study that was conducted in high cholesterol patients taking statins.
Results in Detail
AMG 145, a fully human monoclonal antibody, is a PCSK9 inhibitor. The phase Ib study (n=51) was conducted to evaluate the safety, efficacy and tolerability of AMG145 compared to placebo. Results showed that patients on … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards
|
